RESEARCH

No effect of 10 weeks erythropoietin treatment on lipid oxidation in healthy men

Jeyanthini Risikesan1, Birgitte Nellemann1,2, Britt Christensen1, Jens Otto Lunde Jørgensen1 and Søren Nielsen1,3

1Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark
2Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
3Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark

Correspondence should be addressed to S Nielsen: nielsen.soren@dadlnet.dk

Abstract

Studies indicate that erythropoietin (EPO) has effect on lipid and energy metabolism; however, the impact of EPO on lipid oxidation in vivo has not been well documented. Here, we evaluate whether long-term erythropoiesis-stimulating agent (ESA) treatment affects the oxidation of plasma very low-density lipoprotein triglycerides (VLDL-TG) fatty acids (FA), plasma free fatty acids (FFA) and non-plasma (residual) FA in healthy, young, sedentary men. Infusion of [1-14C]VLDL-TG and [9,10-3H]palmitate was used in combination with indirect calorimetry to assess resting lipid fuel utilization and kinetics, and resting energy expenditure (REE) before and after 10 weeks of ESA exposure compared with placebo. REE increased significantly during ESA compared with placebo (P = 0.023, RM-ANOVA). Oxidation rates of VLDL-TG FA, FFA, and residual FA remained unchanged during ESA compared with placebo. The relative contribution of the lipid stores was greatest for FFA (47.1%) and the total lipid oxidation rate and was not significantly different between ESA and placebo-treated subjects. We conclude that long-term ESA treatment of healthy young men increases REE but does not alter the oxidation rates of plasma and non-plasma FA sources.

Introduction

Human recombinant erythropoietin (rHuEpo) was introduced in 1989 for human use in patients with chronic renal failure, anemia and cancer, to increase hemoglobin mass and red blood cell volume, and to promote aerobic exercise capacity (1, 2). Since then, studies have shown that erythropoietin (EPO) has other protective functions, such as inhibition of inflammation and apoptosis, antioxidant effects, protection against ischemia-induced damage, ischemia-reperfusion, trauma, and stimulation of angiogenesis (3, 4). Some reports have also documented that EPO improves metabolic parameters in patients with diabetes, including fasting glucose levels, diet-induced weight gain, and insulin sensitivity (2, 5, 6, 7, 8, 9). Other studies indicate that EPO has effects on lipid and energy metabolism. However, the mechanisms behind these effects remain unclear (10, 11, 12, 13).

Treatment with rHuEpo has been reported to improve insulin sensitivity and dyslipidemia in patients with end-stage renal disease, independent of correction of anemia (14, 15, 16, 17, 18, 19, 20, 21). Moreover, a study from our group reported that acute erythropoiesis-stimulating agent (ESA) treatment increases resting energy expenditure (REE) (22) and plasma free fatty acids (FFA) concentrations albeit with non-significant changes in lipolysis (palmitate turnover) in healthy men (22). In addition, Caillaud et al. (4) found no effect on resting lipid oxidation, measured by indirect calorimetry, but improved lipid oxidation, during exercise (75% of VO2max) as well as improved VO2max following 4 weeks of EPO treatment in trained, lean men. However, the improvements in lipid oxidation and in VO2max were not significantly associated, which could suggest an
independent role for EPO. Furthermore, studies from our group have consistently shown that plasma very low-density lipoprotein triglycerides (VLDL-TG) fatty acids (FA) are important substrates for lipid oxidation, contributing with 10%-20% of REE (23) and that the oxidation of all plasma (VLDL-TG FA and FFA) and non-plasma (residual) FA sources increase quantitatively during acute exercise in healthy men (12). Although EPO has shown stimulating effects on energy expenditure, studies regarding oxidation of lipid sources during prolonged EPO treatment are lacking. To our knowledge, no studies have investigated the independent pharmacological impact of long-term EPO treatment on integrated lipid oxidation. We hypothesized, that, long-term EPO treatment increases the oxidation of VLDL-TG FA, plasma FFA and residual FA. We also hypothesized that the increased lipid oxidation is proportional to alterations in REE. To this end, we investigated the effects of 10 weeks of ESA exposure in healthy young sedentary subjects. Infusion of [1-14C]VLDL-TG and [9,10-3H]palmitate was used in combination with indirect calorimetry to assess resting lipid fuel utilization and kinetics.

Protocol
A detailed description of the original study design has been published previously (11). In brief, in the present sub-study, volunteers were allocated in a single-blinded, randomized, parallel design to either a sedentary and placebo treatment control (C) group (n = 9) or a sedentary and ESA (Darbepoetin–α, Aranesp; Amgen, Thousand Oaks, CA) treatment group (n = 8) for 10 weeks. Once a week, ESA was administered subcutaneously at a dose of 40 μg for the first 3 weeks and 20 μg for the remaining 7 weeks. Hematocrit was measured weekly throughout the study. The first three subjects, however, received treatment twice a week for the first 3 weeks, which led to a greater increase in the hematocrit than expected (50–54%). Hence, the number of injections was reduced to once a week. As per protocol, some subjects were intermittently switched to placebo in order to keep the hematocrit value below 55%. From 1 week before the treatment until the end of the study the subjects were supplemented with 100 mg iron orally/day (Ferrosulfat, Ferro Duretter; GlaxoSmithKline, Brentford, UK).

Metabolic study day
The participants arrived by taxi to the Clinical Research Unit (CRU) after an overnight fast (only mineral water was allowed) and were placed in bed under thermoneutral conditions for the rest of the study day. Catheters for infusion were placed in an antecubital vein and in a contralateral heated hand vein in order to obtain arterialized blood. Each study day consisted of a 4-h basal period (T = 0–240 min) and a 2-h hyperinsulinemic-euglycemic period (240–360 min). A primed-constant infusion of [1-14C]triolein labeled VLDL-TG (20% bolus, 80% constant) was administered during the whole study period to measure VLDL-TG kinetics. Blood samples for measurements of plasma VLDL-TG concentration and specific activity (SA) were collected together with 14CO2 in breath samples during the last 30 min of the basal period (T = 210, 225, and 240 min). A 2-h constant infusion of [9,10-3H]palmitate was given from T = 120–240 min to measure palmitate turnover and oxidation. Blood samples for measurements of plasma palmitate concentration and SA as well as plasma 3H2O concentration (dpm/mL) were collected at T = 120, 150, 160, 170, 180, 195, 210, 225, and 240 min. Indirect calorimetry was performed from

Methods
Subjects
Seventeen healthy untrained men (age 18–36 years, BMI < 30 kg/m2) were recruited from an ongoing clinical study investigating the effects of physical training and ESA treatment (Darbepoetin alfa) alone and in combination. The data from the main study (11), as well as the effects on VLDL-TG kinetics in the training and control groups (12) have been published previously. All volunteers were normotensive, nonsmokers, used no medication, and had a normal blood and chemistry panel, lipid profile, fasting plasma glucose, HbA1c, as well as a hematocrit < 45%, a normal ECG and a VO2max < 50 mL/kg/min documented before participation. They were instructed to avoid strenuous physical activity, alcohol intake, or changes in the dietary intake 3 days before the study day. Written informed consent was obtained from all participants, the Central Jutland Regional Committee on Health Research Ethics in Denmark has approved the study (M-20110035) and the study was registered at www.clinicaltrials.gov (clinical trial number NCT01320449).
T = 60–90 min. After completion of the study all catheters were removed, the volunteers had lunch, and when blood glucose had stabilized, they were dismissed.

**VLDL-TG tracer preparation**

The participants attended the CRU after a 12-h overnight fast 1 week before the metabolic study day. An 80 mL blood sample was obtained under sterile conditions from each volunteer to isolate VLDL-TG for *ex vivo* labeling as described earlier (24) with minor modifications. Plasma was immediately separated and then sonicated with 15 µCi of [1-14C]triolein (PerkinElmer) at 5°C for 2 h. The [1-14C]triolein–labeled plasma was transferred to sterile tubes and covered with a saline solution of d=1.006 g/cm³ and ultracentrifuged (50.3 Ti rotor (37,000 g) or 5.4 Ti rotor (37,000 g), Beckman Instruments, Inc. (Palo Alto, CA, USA)) for 18 h and at 10°C. The supernatant containing the labeled VLDL fraction was removed with a Pasteur pipette, and the solution was then passed through a Millipore filter with a pore size of 0.20 µm and stored under sterile conditions at 5°C. A representative sample of the labeled [1-14C]VLDL-TG from all participants was cultured to ensure sterility before autologous infusion.

**Plasma VLDL-TG concentration and SA**

On the metabolic study day, VLDL-TG was isolated from approximately 3 mL plasma by ultracentrifugation. VLDL on the top layer was obtained by slicing the tube approximately 1 cm from the top with a tube slicer (Beckman Instruments, Inc.), and the exact volume was noted. TG content was analyzed on a 300 µL aliquot solution (Glycerol blanked assay; COBAS c111, Roche) and the exact volume was passed through a solution containing 0.5 mL hyamine hydroxide in 1 M methanol, 2 mL 96% ethanol, and one to two drops of phenolphthalein. A color change (pink to clear) occurred when exactly 0.5 mmol CO₂ was trapped in the solution, where after [14C] activity was measured by liquid scintillation counting to <2% counting error.

**Breath 14CO₂ SA**

The activity of 14CO₂ in expired air (IRIS-breath-bags; Wagner Analysen Technik, Bremen, Germany) was used to calculate [1-14C] VLDL-TG FA oxidation. The air was passed through a solution containing 0.5 mL hyamine hydroxide in 1 M methanol, 2 mL 96% ethanol, and one to two drops of phenolphthalein. A color change (pink to clear) occurred when exactly 0.5 mmol CO₂ was trapped in the solution, where after [14C] activity was measured by liquid scintillation counting to <2% counting error.

**Palmitate turnover and oxidation**

A 2-h constant infusion of [9,10-3H] palmitate (0.3 µCi/min; Department of Clinical Physiology and Nuclear Medicine, Aarhus University Hospital, Denmark) was employed to measure systemic palmitate turnover and oxidation. Plasma palmitate concentration and SA were measured using [3H] palmitate oxidation rate (dpm/min) divided by the steady-state palmitate SA (dpm/µmol). The slope of the increase in 3H₂O in total body water vs time to calculate 3H₂O production rate (T=120–240 min) was used to measure oxidation of plasma palmitate. The rate of 3H₂O production (dpm/mL/min) was divided by the average plasma [3H]palmitate SA during the same period to calculate plasma palmitate oxidation rates. The plasma 3H₂O concentration and body water were determined as described previously (12, 25, 26).

**Body composition**

At the end of both metabolic study days, Dual-energy X-ray absorptiometry (QDR-2000, Hologic Marlborough, MA, USA) was performed to measure total body fat mass (FM), fat percentage, and lean body mass (LBM).

**Indirect calorimetry**

Indirect calorimetry (Deltatrac monitor, Datex Instrumentarium, Helsinki, Finland) was used to measure REE and respiratory exchange ratio (RER). Net lipid and glucose oxidation were calculated after correction for protein oxidation (27). Urine was collected during the basal period and used to calculate protein oxidation from urea excretion.

**Calculations**

VLDL-TG secretion rate (µmol/min)=VLDL-TG infusion rate/VLDL-TG SA

VLDL-TG clearance rate (mL/min)=VLDL-TG secretion rate/(C_{VLDL-TG})

Fractional VLDL-TG oxidation (% of the infused tracer)=([14CO₂ SA × VCO₂]/(k × Ar × F)), where k is the volume of CO₂ at 20°C and 1 atm. pressure (22.4 L/mol), Ar is the fractional acetate carbon recovery factor in breath CO₂ (0.56 at rest) (28), and F is the tracer infusion rate.
Results

Patient characteristics are shown in Table 1. LBM was not significantly different between the two groups, but decreased significantly during the intervention (ANOVA, time effect, \( P = 0.04 \)).

Post hoc testing could not identify a significant decrease in any of the two groups, but no significant interaction of the intervention was found. As reported previously, hemoglobin, hematocrit, plasma FFA concentrations, and REE increased significantly in the ESA treated group compared with placebo, whereas BMI, plasma insulin and lipids, insulin sensitivity (M-value), palmitate turnover, total fat mass, and % body fat remained unchanged in the two groups.

VLDL-TG kinetics

VLDL-TG oxidation and secretion rates did not change significantly during the intervention (Figs 1A and 2). Similar results were obtained when the analyses were performed without using LBM as covariate in the statistical testing. Fractional VLDL-TG oxidation (%) (i.e. the percent of circulating VLDL-TG FAs that are oxidized) was greater in the ESA compared with the placebo group, but no significant interaction between groups was observed (C-before: 47.9 ± 1.8; C-after: 53.5 ± 4.4; ESA-before: 44.6 ± 1.6; ESA-after: 53.5 ± 4.1 (RM-ANOVA, \( P = 0.024 \) for group difference). VLDL-TG clearance rate remained unaltered (data not shown).

Plasma FFA oxidation rate

Plasma FFA oxidation rate was not significantly different between the groups during the intervention (Fig. 1B). Similarly, no significant difference was observed when the analyses were performed without using LBM as covariate in the statistical testing.
Residual FA oxidation rate

No significant difference was found in residual FA oxidation rate between the groups during the intervention (Fig. 1C).

REE and substrate oxidation rates

The contribution of the different FA sources to total lipid oxidation is shown in Table 2. Total lipid oxidation and residual FA was significantly greater in the ESA group compared with the placebo group, but no significant interaction with treatment was observed. In relative terms (% of total lipid oxidation), residual FA oxidation was significantly greater and FFA oxidation significantly lower in the ESA group compared with the placebo group, but, again, no significant interaction with treatment was found.

As aforementioned, REE increased significantly during ESA compared with placebo (Table 1). When LBM was entered as a covariate in the analyses the increase in REE was no longer significant ($P=0.09$). There were no significant correlations between changes in REE and the individual lipid oxidation rates.

Glucose, protein and lipid oxidation rates as measured by indirect calorimetry were not significantly different between the two groups and did not change significantly during the intervention.

Discussion

The present study is the first to assess the pharmacological effect of long-term erythropoiesis stimulation on plasma and non-plasma FA oxidation rates. We found no significant effects of 10 weeks ESA vs placebo exposure on VLDL-TG FA oxidation or secretion rates or in plasma FFA oxidation rates. Consequently, as total lipid oxidation was significantly greater and FFA oxidation significantly lower in the ESA group compared with the placebo group, but, again, no significant interaction with treatment was found.

As aforementioned, REE increased significantly during ESA compared with placebo (Table 1). When LBM was entered as a covariate in the analyses the increase in REE was no longer significant ($P=0.09$). There were no significant correlations between changes in REE and the individual lipid oxidation rates.

Glucose, protein and lipid oxidation rates as measured by indirect calorimetry were not significantly different between the two groups and did not change significantly during the intervention.
not altered, the residual FA oxidation was also unaffected by ESA treatment.

This present study is unique in that it investigates the combined effects on VLDL-TG FA and FFA oxidation, as well as whole-body substrate oxidation rates using validated methods (11, 12, 27). Even though ESA treatment was associated with an increase in REE we did not observe any significant changes in the oxidation rates of plasma and non-plasma FA sources. Moreover, we found no significant correlations between changes in REE and FA oxidation rates. We, therefore, conclude that ESA treatment of healthy, sedentary men has no major impact on oxidation of individual lipid fuel sources. Previous studies have reported greater (22) or unchanged (29) REE following ESA treatment of healthy individuals. In the present study we were unable to demonstrate significant changes in the overall oxidation of glucose, lipids or proteins despite the significant increase in REE during ESA treatment. Since body weight and body composition were not altered during the treatment period, we, therefore, cannot rule out that our ESA treated participants increased their food intake during the treatment period compared with those in the placebo group, thereby remaining weight stable. The mechanism whereby ESA facilitates a potential increase in REE is so far not understood in detail. We previously reported uncoupling protein 2 (UCP2) mRNA to be significantly greater during long-term ESA compared with placebo, which could account for some of the calorogenic effect of ESA (11). Still, increased UCP2 activity relies on preceding substrate oxidation. Hence, our inability to demonstrate significant differences in individual substrate oxidation rates precludes any speculation regarding which mechanisms might be involved in a potential ESA driven change in REE.

Few studies, including the present one (22), have examined the influence of rHuEpo treatment on the circulating lipid profile and the results are controversial (5, 30, 31, 32, 33). Buccianti et al. demonstrated that rHuEpo in some patients increased cholesterol and triglyceride and reduced HDL cholesterol, and suggested that these results might be attributed to increase in food intake (5). In comparison, administration of rHuEpo in hemodialysis patients has been reported to have no effect on lipid and lipoprotein patterns neither acutely (5) nor at doses varying from 1.5 to 500 units per kilogram of body weight for a period of 14–29 weeks (34). Importantly, other effects of ESA may secondarily affect lipid metabolism. One trial (35) described normalization of several hypothalamic–pituitary–gonadal systems after the use of rHuEpo, which in turn may improve the lipid profile.

There are limitations to the study. First, the limited number of participants recruited, although the statistical power was high enough to show significant results for the dependent variables. Second, the results might have been different, if the population investigated were either females, obese, had increased basal VLDL-TG secretion, augmented intrahepatic content or were insulin resistant. Other studies have described sex-difference in lipid metabolism including both FFA and VLDL (36, 37). Third, consumption of food was not recorded in the current study. Fourth, palmitate was chosen as a representative FA (38). However, previous studies have pointed toward different uptake of individual FFA’s in different tissue beds (38). Therefore, small differences between palmitate and total FFA turnover and oxidation cannot be completely ruled out.

In conclusion, ESA treatment of healthy young men does not alters neither total nor proportional lipid fuel oxidation or metabolism despite a concomitant increase in REE. The mechanisms behind this paradox is unknown, but could be a complex interplay between unaccounted for changes in energy expenditure and/or physical fitness in combination with increased food intake. Further studies are needed in order to investigate the mechanistic effects of EPO in healthy subjects.

Declaration of interest
Jens Otto Jørgensen is a Senior Editor for Endocrine Connections. J O J was not involved in the review or editorial process for this paper, on which he is listed as an author.

Funding
The World Anti-Doping Agency, Independent Research Fund Denmark, Denmark, and Clinical Institute, Aarhus University, Denmark, kindly supported this study.

Acknowledgements
The authors thank Lone Kvist, Susanne Sørensen, Elsebeth Hornemann, Hanne F Petersen, Kirsten Nyborg Rasmussen, and Eva Schriver for excellent technical assistance.

References
1 Fisher JW. Erythropoietin: physiology and pharmacology update. Experimental Biology and Medicine 2003 228 1–14. (https://doi.org/10.1177/1535370203228000101)
2 Hojman P, Taudorf S, Lundby C & Pedersen BK. Erythropoietin augments the cytokine response to acute endotoxin-induced inflammation in humans. Cytokine 2009 45 154–157. (https://doi.org/10.1016/j.cyto.2008.12.005)
3 Lundby C & Olsen NV. Effects of recombinant human erythropoietin in normal humans. Journal of Physiology 2011 589 1265–1271. (https://doi.org/10.1113/jphysiol.2010.195917)
Erythropoietin treatment and lipid oxidation

J Risikesan et al. Erythropoietin treatment and lipid oxidation

18 Mak RH. Effect of recombinant human erythropoietin on insulin, amino acid, and lipid metabolism in uremia. Journal of Pediatrics 1996 129 97–104. (https://doi.org/10.1001/jpeds.1996.10022-3476/96/70195-6)

19 Spaé S, Pangalos M, Askepidis N, Pazaroglou M, Mavropoulou E, Theodoridis S, Dimitrakopoulos K, Millionis A & Vayonas G. Effect of short-term rHuEPO treatment on insulin resistance in haemodialysis patients. Nephron 2000 84 320–325. (https://doi.org/10.1159/000045606)

20 Tuzcu A, Bahceci M, Yilmaz E, Bahcecci S & Tuzcu S. The comparison of insulin sensitivity in non-diabetic haemodialysis patients treated with and without recombinant human erythropoietin. Hormone and Metabolic Research 2004 36 716–720. (https://doi.org/10.1055/s-2004-826021)

21 Allegra V, Mengozzi G, Martimbianco L & Vasile A. Early and late effects of erythropoietin on glucose metabolism in maintenance haemodialysis patients. American Journal of Nephrology 1996 16 304–308. (https://doi.org/10.1159/000069014)

22 Christensen B, Vendelbo MH, Kruusenstjerna-Hafstrom T, Madsen M, Pedersen SB, Jørgensen JS, Nøller N & Jørgensen JOL. Erythropoietin administration acutely stimulates resting energy expenditure in healthy young men. Journal of Applied Physiology 2012 112 1114–1121. (https://doi.org/10.1152/japplphysiol.01391.2011)

23 Sondergaard E, Nelllemann B, Sorensen LP, Christiansen B, Gormsen LC & Nielsen S. Lean body mass, not FFA, predicts VLDL-TG secretion rate in healthy men. Obesity 2015 23 1379–1385. (https://doi.org/10.1002/oby.21108)

24 Gormsen LC, Jensen MD & Nielsen S. Measuring VLDL-triglyceride turnover in humans using ex vivo-prepared VLDL tracer. Journal of Lipid Research 2006 47 99–106. (https://doi.org/10.1194/jlr.M500205-JLR200)

25 Guo Z, Burguera B & Jensen MD. Kinetics of intramuscular triglyceride fatty acids in exercising humans. Journal of Applied Physiology 2000 89 2057–2064. (https://doi.org/10.1152/japplphysiol.2000.89.5.2057)

26 Koutsari LS, Coggan AR, Gastaldelli A & Wolfe RR. A new correction factor for use in tracer estimations of plasma fatty acid oxidation. American Journal of Physiology 1995 269 E649–E656. (https://doi.org/10.1152/ajpendo.1995.269.4.E649)

27 Sondergaard E, Rahbek I, Sorensen LP, Christiansen JS, Gormsen LC, Jensen MD & Nielsen S. Effects of exercise on VLDL-triglyceride oxidation and turnover. American Journal of Physiology: Endocrinology and Metabolism 2011 300 E939–E944. (https://doi.org/10.1152/ajpendo.00031.2011)

28 Sidossis LS, Coggan AR, Gastaldelli A & Wolfe RR. A new correction factor for use in tracer estimations of plasma fatty acid oxidation. American Journal of Physiology 1995 269 E649–E656. (https://doi.org/10.1152/ajpendo.1995.269.4.E649)

29 Lundby C, Robach P, Boushel R, Thomsen J, Rasmussen P, Koskolou M & Calbet JAL. Does recombinant human Epo increase exercise capacity by means other than augmenting oxygen transport? Journal of Applied Physiology 2008 105 581–587. (https://doi.org/10.1152/japplphysiol.00484.2008)

30 Mat O, Stolear JC & Georges B. Blood lipid profile in hemodialysis patients treated with human erythropoietin. Nephron 1992 60 236–237. (https://doi.org/10.1159/0000186747)

31 Prata MM, Sousa FT, Barbas JM & Rodrigues MC. Blood lipids in haemodialysis patients treated with erythropoietin. Nephrology, Dialysis, Transplantation 1990 5 474. (https://doi.org/10.1093/ndt/5.6.474)

32 Viron B, Donsimoni R, Michel C, al Khayat R & Mignon F. Effect of recombinant human erythropoietin on nutritional status and plasma lipids in uremic patients. Nephron 1992 60 249. (https://doi.org/10.1159/000186755)

33 Pollock CA, Wyndham R, Collett PV, Elder G, Field MJ, Kalowski S, Lawrence JR, Waugh DA & George CR. Effects of erythropoietin in...
therapy on the lipid profile in end-stage renal failure. *Kidney International* 1994 45 897–902. (https://doi.org/10.1038/ki.1994.118)

34 Eschbach JW, Egrie JC, Downing MR, Browne JK & Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. *New England Journal of Medicine* 1987 316 73–78. (https://doi.org/10.1056/NEJM198701083160203)

35 Schaefer RM, Kokot F, Kuerner B, Zech M & Heidland A. Normalization of serum prolactin levels in hemodialysis patients on recombinant human erythropoietin. *International Journal of Artificial Organs* 1989 12 445–449.

36 Mittendorfer B, Patterson BW & Klein S. Effect of sex and obesity on basal VLDL-triacylglycerol kinetics. *American Journal of Clinical Nutrition* 2003 77 573–579. (https://doi.org/10.1093/ajcn/77.3.573)

37 Gormsen LC, Jensen MD, Schmitz O, Moller N, Christiansen JS & Nielsen S. Energy expenditure, insulin, and VLDL-triglyceride production in humans. *Journal of Lipid Research* 2006 47 2325–2332. (https://doi.org/10.1194/jlr.M600175-JLR200)

38 Nielsen S, Guo Z, Albu JB, Klein S, O’Brien PC & Jensen MD. Energy expenditure, sex, and endogenous fuel availability in humans. *Journal of Clinical Investigation* 2003 111 981–988. (https://doi.org/10.1172/JCI116253)

Received in final form 18 August 2020
Accepted 13 October 2020
Accepted Manuscript published online 13 October 2020